Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.

Marchese U, Ewald J, Gilabert M, Delpero JR, Turrini O.

J Visc Surg. 2018 Jul 16. pii: S1878-7886(18)30092-4. doi: 10.1016/j.jviscsurg.2018.06.014. [Epub ahead of print]

PMID:
30026012
2.

Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes.

Lomberk G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, Mathison A, Sun Z, Yan H, Elarouci N, Armenoult L, Ayadi M, Ordog T, Lee JH, Oliver G, Klee E, Moutardier V, Gayet O, Bian B, Duconseil P, Gilabert M, Bigonnet M, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Secq V, De Reyniès A, Dusetti N, Iovanna J, Urrutia R.

Nat Commun. 2018 May 17;9(1):1978. doi: 10.1038/s41467-018-04383-6.

3.

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.

Faure M, Rochigneux P, Olive D, Taix S, Brenot-Rossi I, Gilabert M.

Front Immunol. 2018 Apr 19;9:797. doi: 10.3389/fimmu.2018.00797. eCollection 2018.

4.

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts.

Nicolle R, Blum Y, Marisa L, Loncle C, Gayet O, Moutardier V, Turrini O, Giovannini M, Bian B, Bigonnet M, Rubis M, Elarouci N, Armenoult L, Ayadi M, Duconseil P, Gasmi M, Ouaissi M, Maignan A, Lomberk G, Boher JM, Ewald J, Bories E, Garnier J, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Grandval P, Barraud-Blanc M, Norguet E, Gilabert M, Delpero JR, Roques J, Calvo E, Guillaumond F, Vasseur S, Urrutia R, de Reyniès A, Dusetti N, Iovanna J.

Cell Rep. 2017 Nov 28;21(9):2458-2470. doi: 10.1016/j.celrep.2017.11.003.

5.

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.

Monneur A, Goncalves A, Gilabert M, Finetti P, Tarpin C, Zemmour C, Extra JM, Tallet A, Lambaudie E, Jacquemier J, Houvenaeghel G, Boher JM, Viens P, Bertucci F.

Oncotarget. 2017 Jul 31;8(39):66019-66032. doi: 10.18632/oncotarget.19732. eCollection 2017 Sep 12.

6.

A 25-gene classifier predicts overall survival in resectable pancreatic cancer.

Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F.

BMC Med. 2017 Sep 20;15(1):170. doi: 10.1186/s12916-017-0936-z.

7.

An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

Raoul JL, Gilabert M, Adhoute X, Edeline J.

Expert Opin Pharmacother. 2017 Oct;18(14):1467-1476. doi: 10.1080/14656566.2017.1378346. Epub 2017 Sep 14. Review.

PMID:
28893090
8.

How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?

Gilabert M, Raoul JL, Rousseau F.

J Geriatr Oncol. 2017 Nov;8(6):407-412. doi: 10.1016/j.jgo.2017.08.007. Epub 2017 Sep 6. Review.

PMID:
28888554
9.

Resectable pancreatic head adenocarcinoma: Is R0 resection an illusion? Genetic evaluation of venous resection margin affirmed unrecognized disease.

Turrini O, Gilabert M, Ewald J, Moutardier V, Delpero JR, Iovanna JL.

J Visc Surg. 2017 Oct;154(5):329-333. doi: 10.1016/j.jviscsurg.2017.05.009. Epub 2017 Aug 23.

PMID:
28844705
10.

To TACE or not to TACE? Lessons from a negative trial.

Raoul JL, Gilabert M, Adhoute X.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):541-543. doi: 10.1016/S2468-1253(17)30181-4. Epub 2017 Jun 23. No abstract available.

11.

Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: A retrospective analysis by the Association Française de Chirurgie.

Gilabert M, Boher JM, Raoul JL, Paye F, Bachellier P, Turrini O, Delpero JR; Association Française de Chirurgie.

Medicine (Baltimore). 2017 Jun;96(24):e7214. doi: 10.1097/MD.0000000000007214.

12.

Hepatocellular Carcinoma: Slow Progress in a Booming Epidemic.

Raoul JL, Gilabert M.

J Oncol Pract. 2017 Jun;13(6):365-366. doi: 10.1200/JOP.2017.024364. No abstract available.

PMID:
28605618
13.

An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value.

Andriantsoa M, Hoibian S, Autret A, Gilabert M, Sarran A, Niccoli P, Raoul JL.

PLoS One. 2017 May 31;12(5):e0177971. doi: 10.1371/journal.pone.0177971. eCollection 2017.

14.

Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study.

Rho YS, Gilabert M, Polom K, Aladashvili A, Kopeckova K, Megdanova V, Coleman N, Greally M, Marrelli D, Roviello F, McDermott R, Petrova V, Mihaylova Z, Bortlicek Z, Prausova J, Batist G, Azoulay L, Kavan P.

Clin Colorectal Cancer. 2017 Dec;16(4):334-342. doi: 10.1016/j.clcc.2017.03.008. Epub 2017 Mar 21.

PMID:
28462853
15.

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.

Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, Kavan P, Raoul JL.

Medicine (Baltimore). 2017 Apr;96(16):e6544. doi: 10.1097/MD.0000000000006544.

16.

A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study.

Chanez B, Bertucci F, Gilabert M, Madroszyk A, Rousseau F, Perrot D, Viens P, Raoul JL.

Support Care Cancer. 2017 Sep;25(9):2715-2722. doi: 10.1007/s00520-017-3680-1. Epub 2017 Mar 28.

PMID:
28353038
17.

Prognostic Value of Molecular Subtypes in Pancreatic Cancer.

Bertucci F, Birnbaum DJ, Finetti P, Gilabert M, Poizat F, Raoul JL, Birnbaum D, Mamessier E.

Pancreas. 2017 Apr;46(4):e29-e31. doi: 10.1097/MPA.0000000000000787. No abstract available.

PMID:
28291163
18.

Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts.

Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilabert M, Moutardier V, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Ouaissi M, Secq V, Poizat F, Nicolle R, Blum Y, Marisa L, Rubis M, Raoul JL, Bradner JE, Qi J, Lomberk G, Urrutia R, Saul A, Dusetti N, Iovanna J.

EMBO Mol Med. 2017 Apr;9(4):482-497. doi: 10.15252/emmm.201606975.

19.

How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma.

Raoul JL, Adhoute X, Gilabert M, Edeline J.

World J Hepatol. 2016 Dec 18;8(35):1541-1546. doi: 10.4254/wjh.v8.i35.1541. Review.

20.

Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas.

Gilabert M, Rho YS, Kavan P.

Oncology. 2017;92(3):170-172. doi: 10.1159/000452279. Epub 2016 Nov 12.

PMID:
27838688
21.

Prognostic value of PDL1 expression in pancreatic cancer.

Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Turrini O, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F.

Oncotarget. 2016 Nov 1;7(44):71198-71210. doi: 10.18632/oncotarget.11685.

22.

A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.

Barraud M, Garnier J, Loncle C, Gayet O, Lequeue C, Vasseur S, Bian B, Duconseil P, Gilabert M, Bigonnet M, Maignan A, Moutardier V, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Ouaissi M, Secq V, Poizat F, Guibert N, Iovanna J, Dusetti N.

Oncotarget. 2016 Aug 16;7(33):53783-53796. doi: 10.18632/oncotarget.10776.

23.

Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study.

Decoster C, Gilabert M, Autret A, Turrini O, Oziel-Taieb S, Poizat F, Giovannini M, Viens P, Iovanna J, Raoul JL.

Oncotarget. 2016 Jul 19;7(29):45649-45655. doi: 10.18632/oncotarget.9861.

24.

The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research.

Luque RM, Ibáñez-Costa A, Sánchez-Tejada L, Rivero-Cortés E, Robledo M, Madrazo-Atutxa A, Mora M, Álvarez CV, Lucas-Morante T, Álvarez-Escolá C, Fajardo C, Castaño L, Gaztambide S, Venegas-Moreno E, Soto-Moreno A, Gálvez MÁ, Salvador J, Valassi E, Webb SM, Picó A, Puig-Domingo M, Gilabert M, Bernabéu I, Marazuela M, Leal-Cerro A, Castaño JP; investigadores del REMAH.

Endocrinol Nutr. 2016 Jun-Jul;63(6):274-84. doi: 10.1016/j.endonu.2016.03.001. Epub 2016 Apr 16. English, Spanish.

PMID:
27091627
25.

Active sesquiterpene lactones against Leishmania amazonensis and Leishmania braziliensis.

Sosa AM, Amaya S, Salamanca Capusiri E, Gilabert M, Bardón A, Giménez A, Vera NR, Borkosky SA.

Nat Prod Res. 2016 Jan 12:1-5. [Epub ahead of print]

PMID:
26755152
26.

Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer.

McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, Batist G, Kavan P.

Clin Colorectal Cancer. 2016 Jun;15(2):135-40. doi: 10.1016/j.clcc.2015.10.003. Epub 2015 Oct 21.

PMID:
26553578
27.

Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients.

Oziel-Taieb S, Faure M, Gilabert M, Autret A, Turrini O, Moureau-Zabotto L, Giovannini M, Rousseau F, Raoul JL.

J Gastrointest Cancer. 2016 Mar;47(1):15-9. doi: 10.1007/s12029-015-9774-4.

PMID:
26545612
28.

Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.

Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL.

Liver Cancer. 2015 Mar;4(1):16-25. doi: 10.1159/000343878. Review.

29.

Antioxidant activity and chemical composition of essential oils of three aromatic plants from La Rioja province.

Barbieri N, Costamagna M, Gilabert M, Perotti M, Schuff C, Isla MI, Benavente A.

Pharm Biol. 2016;54(1):168-73. doi: 10.3109/13880209.2015.1028077. Epub 2015 Apr 13.

PMID:
25865139
30.

Intermediate-stage HCC--upfront resection can be feasible.

Forner A, Gilabert M, Bruix J, Raoul JL.

Nat Rev Clin Oncol. 2015 May;12(5). doi: 10.1038/nrclinonc.2014.122-c4. Epub 2015 Apr 7. No abstract available.

PMID:
25850552
31.

Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.

Molejon MI, Tellechea JI, Loncle C, Gayet O, Gilabert M, Duconseil P, Lopez-Millan MB, Moutardier V, Gasmi M, Garcia S, Turrini O, Ouaissi M, Poizat F, Dusetti N, Iovanna J.

Oncotarget. 2015 Apr 10;6(10):7408-23.

32.

Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma.

Duconseil P, Gilabert M, Gayet O, Loncle C, Moutardier V, Turrini O, Calvo E, Ewald J, Giovannini M, Gasmi M, Bories E, Barthet M, Ouaissi M, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Viens P, Iovanna J, Dusetti N.

Am J Pathol. 2015 Apr;185(4):1022-32. doi: 10.1016/j.ajpath.2014.11.029. Epub 2015 Mar 9.

PMID:
25765988
33.

Solid pancreatic tumors in patients younger than 40 years old--experience of a French comprehensive cancer center.

Gilabert M, Turrini O, Niccoli P, Moureau-Zabotto L, Boher JM, Poizat F, Giovannini M, Delpero JR, Raoul JL.

Pancreas. 2015 Mar;44(2):345-6. doi: 10.1097/MPA.0000000000000221. No abstract available.

PMID:
25675423
34.

Sesqui- and triterpenoids from the liverwort Lepidozia chordulifera inhibitors of bacterial biofilm and elastase activity of human pathogenic bacteria.

Gilabert M, Marcinkevicius K, Andujar S, Schiavone M, Arena ME, Bardón A.

Phytomedicine. 2015 Jan 15;22(1):77-85. doi: 10.1016/j.phymed.2014.10.006. Epub 2014 Oct 25.

PMID:
25636875
35.

Hepatocellular carcinoma in a noncirrhotic liver after long-term use of danazol for hereditary angioedema.

Rahal S, Gilabert M, Ries P, Oziel-Taieb S, Dermeche S, Raoul JL.

Case Rep Oncol. 2014 Dec 9;7(3):825-7. doi: 10.1159/000370106. eCollection 2014 Sep-Dec.

36.

A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor.

Gayet O, Loncle C, Duconseil P, Gilabert M, Lopez MB, Moutardier V, Turrini O, Calvo E, Ewald J, Giovannini M, Gasmi M, Bories E, Barthet M, Ouaissi M, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Viens P, Dusetti N, Iovanna J.

Oncotarget. 2015 Jan 20;6(2):746-54.

37.

Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.

Forner A, Gilabert M, Bruix J, Raoul JL.

Nat Rev Clin Oncol. 2015 Jan;12(1):10. doi: 10.1038/nrclinonc.2014.122-c2. Epub 2014 Nov 25. No abstract available.

PMID:
25421282
38.

Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib.

Gilabert M, Launay S, Ginestier C, Bertucci F, Audebert S, Pophillat M, Toiron Y, Baudelet E, Finetti P, Noguchi T, Sobol H, Birnbaum D, Borg JP, Charafe-Jauffret E, Gonçalves A.

PLoS One. 2014 Aug 21;9(8):e104302. doi: 10.1371/journal.pone.0104302. eCollection 2014.

39.

Treatment of intermediate-stage hepatocellular carcinoma.

Forner A, Gilabert M, Bruix J, Raoul JL.

Nat Rev Clin Oncol. 2014 Sep;11(9):525-35. doi: 10.1038/nrclinonc.2014.122. Epub 2014 Aug 5. Review.

PMID:
25091611
40.

How to define transarterial chemoembolization failure or refractoriness: a European perspective.

Raoul JL, Gilabert M, Piana G.

Liver Cancer. 2014 May;3(2):119-24. doi: 10.1159/000343867. Review.

41.

Bazex syndrome revealing a gastric cancer.

Robert M, Gilabert M, Rahal S, Ries P, Raoul JL.

Case Rep Oncol. 2014 Apr 30;7(1):285-7. doi: 10.1159/000362787. eCollection 2014 Jan.

42.

One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization.

Servajean C, Gilabert M, Piana G, Monges G, Delpero JR, Brenot I, Raoul JL.

World J Gastroenterol. 2014 May 7;20(17):5131-4. doi: 10.3748/wjg.v20.i17.5131.

43.

[Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].

Gilabert M, Launay S, Gonçalves A.

Bull Cancer. 2014 Mar;101(3):325-33. doi: 10.1684/bdc.2014.1910. Review. French.

PMID:
24691195
44.

Pancreatic cancer-induced cachexia is Jak2-dependent in mice.

Gilabert M, Calvo E, Airoldi A, Hamidi T, Moutardier V, Turrini O, Iovanna J.

J Cell Physiol. 2014 Oct;229(10):1437-43. doi: 10.1002/jcp.24580.

PMID:
24648112
45.

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma.

Gilabert M, Provansal M, Cappiello M, Walz Y, Salem N, Tarpin C, Brunelle S, Thomassin J, Gravis G.

Br J Cancer. 2013 Oct 1;109(7):1750-4. doi: 10.1038/bjc.2013.516. Epub 2013 Sep 17.

46.

Toxicity of Porella chilensis sesqui- and diterpenoids against larvae of the corn pest Spodoptera frugiperda (J.E. Smith) (Lepidotera: Noctuidae).

Corzo FL, Gilabert M, Alcaide MF, Bardón A.

Neotrop Entomol. 2012 Oct;41(5):414-9. doi: 10.1007/s13744-012-0059-3. Epub 2012 Jul 4.

PMID:
23950093
47.

[Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].

Gonçalves A, Sabatier R, Charafe-Jauffret E, Gilabert M, Provansal M, Tarpin C, Extra JM, Viens P, Bertucci F.

Bull Cancer. 2013 May;100(5):453-64. doi: 10.1684/bdc.2013.1740. Review. French.

PMID:
23695030
48.

[Palliative treatment for hepatocellular carcinoma].

Raoul JL, Gilabert M, Oziel-Taïeb S, Giovannini M.

Rev Prat. 2013 Feb;63(2):233-6. Review. French.

PMID:
23513793
49.

Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs.

Gilabert M, Vaccaro MI, Fernandez-Zapico ME, Calvo EL, Turrini O, Secq V, Garcia S, Moutardier V, Lomberk G, Dusetti N, Urrutia R, Iovanna JL.

J Cell Physiol. 2013 Sep;228(9):1834-43. doi: 10.1002/jcp.24343.

50.

[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].

Bachelot T, Le Rhun E, Labidi-Gally I, Heudel P, Gilabert M, Bonneterre J, Pierga JY, Gonçalves A.

Bull Cancer. 2013 Jan 1;100(1):7-14. doi: 10.1684/bdc.2012.1676. Review. French.

Supplemental Content

Loading ...
Support Center